Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Qiyu Biotech

Request full access

Qiyu Biotech is an innovative macromolecular drug developer

Huangpu, ChinaFounded 2017Biotech & Life Sciences

About Qiyu Biotech

Qiyu Biotechnology (Shanghai) Co., Ltd., which also operates under the name QureBio, is a clinical-stage biopharmaceutical company established in July 2017. The firm was founded by Xiangdong Qu, a scientist with approximately two decades of experience in new drug research and development at prominent U.S. companies, including Amgen, Eli Lilly, and Cell Therapeutics Inc. This background in international pharmaceutical R&D provides the foundation for the company's strategic direction. The core team is composed of scientists with deep expertise in antibody engineering and manufacturing processes.

The company's primary business is the research and development of innovative macromolecular drugs to address unmet clinical needs in refractory cancers, autoimmune diseases, inflammatory disorders, and metabolic diseases. Its operational model is centered on leveraging a proprietary suite of technology platforms to create a pipeline of therapeutic candidates. These platforms include systems for hybridoma antibody humanization, phage display, single-domain antibodies, and antibody engineering, such as its I2T platform for bispecific and multispecific antibodies. Qiyu Biotech's revenue generation model involves advancing its internally developed assets through clinical trials and forming strategic partnerships with other pharmaceutical firms for co-development and commercialization. The company has established collaborations with entities like BRL Medicine, BioMap, Hengrui Pharma, and Precision Scientific.

Qiyu Biotech's therapeutic pipeline features several key drug candidates. Its lead product, Q-1802, is a bispecific antibody targeting both Claudin18.2 and PD-L1 for the treatment of solid tumors like gastric cancer. This candidate has received Investigational New Drug (IND) clearance from both U.S. and Chinese regulatory agencies and is advancing through clinical trials. Another significant asset, Q-1801, is a dual-target antibody for SIRPα and PD-L1, which also has clinical trial approvals in the U.S. and China. The company has successfully raised significant capital through multiple funding rounds, including a Series C1 financing of nearly CNY 100 million in June 2025, to advance its clinical programs.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2017
Headquarters
Huangpu, China
Open positions
None listed
Dealroom signal
16.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES C✓Equity / VC Jun 2025 $14M $138M Efung Capital ↗
SERIES B✓Equity / VC Dec 2021 $28M $110M Shanghai Pudong Science and Technology Investment · Yuanhe Puhua · Bank of Communications · Tianfu Sanjiang Capital ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Qiyu Biotech website traffic

Latest recorded traffic for Qiyu Biotech is 650 monthly website visits, down 14.5% over the last three months.

Latest monthly visits650 3-month web change-14.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Qiyu Biotech in the Huangpu ecosystem

Live from Dealroom

The Qiyu Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • Shanghai Pudong Science and Technology Investment
  • Yuanhe Puhua
  • Bank of Communications
  • Tianfu Sanjiang Capital
  • Longmen Capital
  • Guoshun
  • Lihe Hongxin

Series B and later1 investor entered at this stage

  • Efung Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Huangpu HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Qiyu Biotech on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Qiyu Biotech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.